Clinical study on thyroid-associated ophthalmopathy in the elderly

doi:10.3877/cma.j.issn.2095-2007.2019.03.010

Abstract

Abstract:

Thyroid-associated ophthalmopathy is an organ-specific autoimmune disease, which can not only reduce patients′ visual acuity, but also change their appearances, affect their social interaction, psychosocial and other factors, and reduce their life qualities. Eye lesions of the elderly are more complex and have a greater impact on the life qualities of the elderly. However, compared with other age groups, the elderly is easily ignored. This paper will discuss the influencing factors, clinical characteristics, and treatment of thyroid-associated ophthalmopathy in the elderly, in order to remind the clinical attention of the elderly patients, and provide the basis for clinical standard diagnosis and treatment.

Key words: Thyroid-associated ophthalmopathy, The elderly, Clinical characteristics, Therapy

Liping Jing, Jianying Wang, Bin Sun. Clinical study on thyroid-associated ophthalmopathy in the elderly[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2019, 09(03): 182-186.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2019.03.010

https://zhykyxzz.cma-cmc.com.cn/EN/Y2019/V09/I03/182

References 58

[1]	宋国祥. 眼眶病学[M]. 北京：人民军医出版社，1999.
[2]	罗清礼. 甲状腺相关眼病[M]. 北京：人民卫生出版社，2005.
[3]	Gharib S, Moazezi Z, Bayani MA. Prevalence and severity of ocular involvement in Graves′ disease according to sex and age: A clinical study from Babol, Iran[J]. Caspian J Intern Med, 2018, 9(2): 178-183.
[4]	张道敬，张友岩. 即墨地区60岁以上老年人甲状腺眼病的研究调查分析[J]. 中国地方病防治杂志，2016(6)：611-612.
[5]	Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota[J]. Trans Am Ophthalmol Soc, 1994, 92: 477-588.
[6]	Weetman AP. Thyroid-associated eye disease: pathophysiology[J]. Lancet, 1991, 338(8758): 25-28.
[7]	Wall JR, Salvi M, Bernard NF, et al. Thyroid-associated ophthalmopathy--a model for the association of organ-specific autoimmune disorders[J]. Immunol Today, 1991, 12(5): 150-153.
[8]	Weetman AP. Graves′ disease[J]. N Engl J Med, 2000, 343(17): 1236-1248.
[9]	Lehmann GM, Feldon SE, Smith TJ, et al. Immune mechanisms in thyroid eye disease[J]. Thyroid, 2008, 18(9): 959-965.
[10]	Aniszewski JP, Valyasevi RW, Bahn RS. Relationship between disease duration and predominant orbital T cell subset in Graves′ ophthalmopathy[J]. J Clin Endocrinol Metab, 2000, 85(2): 776-780.
[11]	Natt N, Bahn RS. Cytokines in the evolution of Graves′ ophthalmopathy[J]. Autoimmunity, 1997, 26(2): 129-136.
[12]	Wang Y, Smith TJ. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy[J]. Invest Opthalmol Vis Sci, 2014, 55(3): 1735-1748.
[13]	van Steensel L, Paridaens D, van Meurs M, et al. Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves′ ophthalmopathy[J]. J Clin Endocrinol Metab, 2012, 97(3): E400-E408.
[14]	Bednarczuk T, Gopinath B, Ploski R, et al. Susceptibility genes in Graves′ ophthalmopathy: searching for a needle in a haystack？[J]. Clin Endocrinol (Oxf), 2007, 67(1): 3-19.
[15]	Hegediüs L, Brix TH, Vestergaard P. Relationship between cigarette smoking and Graves′ ophthalmopathy[J]. J Endocrinol Invest, 2004, 27(3): 265-271.
[16]	Träisk F, Tallstedt L, Abraham-Nordling M, et al. Thyroid-associated ophthalmopathy after treatment for Graves′ hyperthyroidism with antithyroid drugs or iodine-131[J]. J Clin Endocrinol Metab, 2009, 94(10): 3700-3707.
[17]	Bartalena L, Pinchera A, Marcocci C, et al. Management of Graves′ ophthalmopathy: reality and perspectives[J]. Endocr Rev, 2000, 21(2): 168-199.
[18]	王峰. 动态增强磁共振成像和眼外肌自身抗原的免疫学研究在甲状腺相关眼病中的临床应用[D]. 天津：天津医科大学，2014.
[19]	吴晓，艾立坤，王京辉. 甲状腺相关性眼病的临床特征[J]. 中国斜视与小儿眼科杂志，2004，12(4)：145-149.
[20]	Mourits MP, Koornneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves′ ophthalmopathy: a novel approach[J]. Br J Ophthalmol, 1989, 73(8): 639-644.
[21]	Eckstein AK, Plicht M, Lax H, et al. Clinical results of anti-inflammatory therapy in Graves′ ophthalmopathy and association with thyroidal autoantibodies[J]. Clin Endocrinol (Oxf), 2004, 61(5): 612-618.
[22]	Perros P, Crombie AL, Matthews JN, et al. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic[J]. Clin Endocrinol (Oxf), 1993, 38(4): 367-372.
[23]	Gharib S, Moazezi Z, Bayani MA. Prevalence and severity of ocular involvement in Graves′ disease according to sex and age: A clinical study from Babol, Iran[J]. Caspian J Intern Med, 2018, 9(2): 178-183.
[24]	Sun B, Zhang Z, Dong C, et al. ⁹⁹Tcm-octreotide scintigraphy and serum eye muscle antibodies in evaluation of active thyroid-associated ophthalmopathy[J]. Eye (Lond), 2017, 31(5): 668-676.
[25]	Tanda ML, Piantanida E, Liparulo L, et al. Prevalence and natural history of Graves′ orbitopathy in a large series of patients with newly diagnosed graves′ hyperthyroidism seen at a single center[J]. J Clin Endocrinol Metab, 2013, 98(4): 1443-1449.
[26]	Terwee CB, Prummel MF, Gerding MN, et al. Measuring disease activity to predict therapeutic outcome in Graves′ ophthalmopathy[J]. Clin Endocrinol (Oxf), 2005, 62(2): 145-155.
[27]	Bartalena L, Pinchera A, Marcocci C. Management of Graves′ ophthalmopathy: reality and perspectives[J]. Endocr Rev, 2000, 21(2): 168-199.
[28]	闾倩. miR-143在甲状腺相关性眼病中的作用机制及糖皮质激素临床冲击治疗研究[D]. 上海：第二军医大学，2013.
[29]	Papaleontiou M, Haymart MR. Approach to and treatment of thyroid disorders in the elderly[J]. Med Clin North Am, 2012, 96(2): 297-310.
[30]	Kendler DL, Lippa J, Rootman J. The initial clinical chara-cteristics of Graves′ orbitopathy vary with age and sex[J]. Arch Ophthalmol, 1993, 111(2): 197-201.
[31]	Lazarus JH. Epidemiology of Graves′ orbitopathy (GO) and relationship with thyroid disease[J]. Best Pract Res Clin Endocrinol Metab, 2012, 26(3): 273-279.
[32]	Edmunds MR, Boelaert K. Knowledge of thyroid eye disease in Graves′ disease patients with and without orbitopathy[J]. Thyroid, 2019, 29(4): 557-562.
[33]	Wiersinga W, Žarkovic M, Bartalena L, et al. Predictive score for the development or progression of Graves′ orbitopathy in patients with newly diagnosed Graves′ hyperthyroidism[J]. Eur J Endocrinol, 2018, 178(6): 635-643.
[34]	何剑峰，吴中耀，杨华胜，等. 老年人Graves眼病的临床分析[J]. 中华老年医学杂志，2004，23(3)：172-175.
[35]	Sadeghi-Tari A, Jamshidian-Tehrani M, Nabavi A, et al. Effect of smoking on retrobulbar blood flow in thyroid eye disease[J]. Eye (Lond), 2016, 30(12): 1573-1578.
[36]	Bartalena L, Martino E, Marcocci C, et al. More on smoking habits and Graves′ ophthalmopathy[J]. J Endocrinol Invest, 1989, 12(10): 733-737.
[37]	Le Moli R, Muscia V, Tumminia A, et al. Type 2 diabetic patients with Graves′ disease have more frequent and severe Graves′ orbitopathy[J]. Nutr Metabo Cardiovasc Dis, 2015, 25(5): 452-457.
[38]	Urselli F, Pontieri G, Peschi L, et al. Active moderate-to-severe Graves′ orbitopathy in a patient with type 2 diabetes mellitus and vascular complications[J]. Front Endocrinol (Lausanne), 2019, 9: 810.
[39]	Kalmann R, Mourits MP. Diabetes mellitus: a risk factor in patients with Graves′ orbitopathy[J]. Br J Ophthalmol, 1999, 83(4): 463-465.
[40]	Hansen MP, Matheis N, Kahaly GJ. Type 1 diabetes and polyglandular autoimmune syndrome: A review[J]. World J Diabetes, 2015, 6(1): 67-79.
[41]	姜双东. 中老年人Graves眼病的临床对比研究[J]. 中华现代眼耳鼻喉科杂志，2008，5(3)：211-213.
[42]	Nunery WR. Ophthalmic Graves′ disease: A dual theory of pathogenesis[J]. OphthalmolClin North Am, 1991, 4: 73-87.
[43]	Forbes G, Gorman CA, Brennan MD, et al. Ophthalmopathy of Graves′ disease: computerized volume measurements of the orbital fat and muscle[J]. AJNR Am J Neuroradiol, 1986, 7(4): 651-656.
[44]	危昆桥，魏锐利，马晓晔，等. 甲状腺相关眼病眼眶CT定量测量及亚型分析[J]. 中国实用眼科杂志，2014，32(2)：161-165.
[45]	Ben Simon GJ, Katz G, Zloto O, et al. Age differences in clinical manifestation and prognosis of thyroid eye disease[J]. Graefe′s Arch Clin Exp Ophthalmol, 2015, 253(12): 2301-2308.
[46]	Villadolid MC, Yokoyama N, Izumi M, et al. Untreated Graves′ disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance[J]. J Clin Endocrinol Metab, 1995, 80(9): 2830-2833.
[47]	Mizokami T, Salvi M, Wall JR. Eye muscle antibodies in Graves′ ophthalmopathy: pathogenic or secondary epiphenomenon？[J]. J Endocrinol Invest, 2004, 27(3): 221-229.
[48]	Trobe JD, Glaser JS, Laflamme P. Dysthyroid optic neuropathy. Clinical profile and rationale for management[J]. Arch Ophthalmol, 1978, 96(7): 1199-1209.
[49]	Campbell AA, Nanda T, Oropesa S, et al. Age-related changes in the clinical phenotype of compressive optic neuropathy in thyroid eye disease[J]. Ophthalmic Plast Reconstr Surg, 2019, 35(3): 238-242.
[50]	Weis E, Heran MK, Jhamb A, et al. Quantitative computed tomographic predictors of compressive optic neuropathy in patients with thyroid orbitopathy: a volumetric analysis[J]. Ophthalmology, 2012, 119(10): 2174-2178.
[51]	Callahan AB, Campbell AA, Oropesa S, et al. The columbia thyroid eye disease-compressive optic neuropathy diagnostic formula[J]. Ophthalmic Plast Reconstr Surg, 2018, 34(4): S68-S71.
[52]	黄琼，占梦琪，李凡. 老年甲状腺相关眼病患者视觉相关生存质量及其影响因素的调查[J]. 职业与健康，2015，31(17)：2359-2362.
[53]	Sheck L, Davies J, Wilson G. Selenium and ocular health in New Zealand[J]. N Z Med J, 2010, 123(1316): 85-94.
[54]	Sisti E, Coco B, Menconi F, et al. Age and dose are major risk factors for liver damage associated with intravenous glucocorticoid pulse therapy for Graves′ orbitopathy[J]. Thyroid, 2015, 25(7): 846-850.
[55]	郭树龙，张久君. 相对低剂量甲泼尼龙联合⁹⁹Tc-MDP治疗老年Graves眼病的疗效观察[J]. 国际放射医学核医学杂志，2009，33(5)：287-290.
[56]	Ismailova DS, Belovalova IM, Grusha YO, et al. Orbital decompression in the system of treatment for complicated thyroid eye disease: case report and literature review[J]. Int Med Case Rep J, 2018, 11: 243-249.
[57]	Liang QW, Yang H, Luo W, et al. Effect of orbital decompression on dysthyroid optic neuropathy: A retrospective case series[J]. Medicine (Baltimore), 2019, 98(3): e14162.
[58]	孙丰源，吴桐. 再谈眼眶减压术治疗甲状腺相关眼病的临床价值[J]. 中华眼科杂志，2017，53(6)：401-403.

Please choose a citation manager

Content to export